Osimertinib (TAGRISSO®) is an orally administered, third-generation epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor that is approved for the adjuvant treatment of …

Background Osimertinib is standard-of-care therapy for previously untreated epidermal
growth factor receptor (EGFR) mutation–positive advanced non–small-cell lung cancer …

Introduction Osimertinib is a central nervous system (CNS)-active, third generation,
irreversible, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that …

Background Among patients with resected, epidermal growth factor receptor (EGFR)–
mutated, stage IB to IIIA non–small-cell lung cancer (NSCLC), adjuvant osimertinib therapy …

The introduction of tyrosine kinase inhibitors (TKI) for the treatment of metastatic non-small
cell lung cancer (NSCLC) harbouring sensitizing epidermal growth factor receptor (EGFR) …

Background: In the double-blind phase III ADAURA randomized clinical trial, adjuvant
osimertinib showed a substantial overall survival benefit in patients with stage IB to IIIA …

LBA3 Background: Osimertinib is a third-generation, central nervous system (CNS) active
EGFR-TKI, that potently and selectively inhibits EGFR-TKI sensitizing and EGFR T790M …

8508 Background: Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI)
effective in treating advanced EGFR-mutated non-small cell lung cancer (NSCLC). Adjuvant …

Osimertinib, a third‐generation EGFR tyrosine kinase inhibitor (TKI), is the new first line
standard of care in metastatic non‐small cell lung cancer (NSCLC) based on improvements …

The ADAURA trial was conducted in lung cancer to evaluate the efficacy of adjuvant
osimertinib in patients with early-stage NSCLC who had an EGFR exon 19 deletions and …